ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE
March 26, 1999
SLIDES
Rezulin (Troglitazone) Tablets, Robert Zerbe, MD, Sr. Vice-President, Clinical Research and Development, Parke-Davis Pharmaceutical Research
Hepatic Events, Paul B. Watkins, MD, Director, General Clinical Research Center. Professor of Medicine, Professor Pharmacology, University of Michigan
Incidence of Serious Liver Events, Mark Pierce, MD, PhD, Vice President, Clinical Research, Parke-Davis Pharmaceutical Research
Anti-hyperglycaemic Therapies Comparative Safety, Philip Home, Professor of Diabetes Medicine, University of Newcastle Upon Tyne
Benefits of Rezulin Therapy, Randall Whitcomb, MD, Vice President, Clinical Research, Parke-Davis
Summary of Risk - Benefit Assessment, Robert Zerbe, MD, Sr. Vice-President, Clinical Research and Development, Parke-Davis
Hepatic Events in oral antidiabetic - exposed patients in a Midwestern employer claims database (preliminary data), Judith K. Jones, MD, PhD, The Degge Group, Ltd.
Package Insert